Search

Advanced MRI techniques including diffusion and perfusion weighted imaging, has the potential to provide early surrogate biomarkers to detect, characterize and assess treatment response of tumors. However, the widely accepted Response Evaluation Criteria in Solid Tumors (RECIST) are still considered as the gold standard for the evaluation of treatment response in solid tumors, even if according to recent studies RECIST seem to disregard the extent of necrosis, which is the target of all effective locoregional therapies. This is partly due to the fact that measurements of tumor size aren't the best criterion for assessing actual early response. On the other hand, more sophisticated techniques such as the Apparent Diffusion Coefficient (ADC) and perfusion parameters are usually processed manually and evaluated independently using commercial CAD software, not widely available. In this paper we present an open access extensible software platform providing both diffusion and perfusion analysis in a single, user friendly environment that allows the radiologist to easily and objectively evaluate tumor response to therapy. [ABSTRACT FROM PUBLISHER]